- Tevogen Bio Holdings (TVGN) to participate in BioNJ's Fifteenth Annual Bio Partnering Conference on May 13, 2025.
- CEO Dr. Ryan Saadi joins a panel on 'Paths to Liquidity: Strategies for Adapting to a Volatile Market'.
- Conference features networking and strategic partnership opportunities to boost medical innovation.
Tevogen Bio Holdings (NASDAQ: TVGN) has announced that its CEO, Dr. Ryan Saadi, will be participating in BioNJ's Fifteenth Annual Bio Partnering Conference, scheduled for May 13, 2025, at The Liberty Science Center in Jersey City, NJ. Dr. Saadi is set to join a panel discussion entitled 'Paths to Liquidity: Strategies for Adapting to a Volatile Market', which will be moderated by David C Schwartz, a partner at Morgan Lewis.
The panel will feature industry experts including Matt Vamvakis, Managing Director at J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst at RSM US, and Kee Colon, Managing Director at Cantor Fitzgerald. The discussion will address market volatility and its potential effects on patient outcomes, aligning with Tevogen Bio's mission to advance accessibility and affordability of lifesaving treatments.
BioNJ's conference aims to connect investors, business development professionals, academic collaborators, and biopharmaceutical industry executives to foster strategic partnerships, secure funding, and drive innovation in healthcare. The event's lineup includes one-on-one partnering sessions, company pitch presentations, an Industry Connections Desk, exhibits, and extensive networking opportunities, designed to provide a platform for growth and collaboration.
